Effect of tetrahydrocannabinolcannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity a retrospective, observational study.
To examine evolution in activities of daily living (ADL) in patients with multiple sclerosis spasticity during long-term use of tetrahydrocannabinol (THC)cannabidiol (CBD) oromucosal spray. Functional impairment was assessed retrospectively (prior to start of treatment) and at the present moment using a 16-item ADL survey results were compared. A control group without add-on THCCBD oromucosal spray was included to investigate possible recall bias. ADL was maintained or slightly improved with THCCBD oromucosal spray across treatment time (mean 31.9 months) including significant improvement in standing up (p < 0.05) and trends in other items. Significant improvements (p < 0.01) with THCCBD oromucosal spray were observed in several multiple sclerosis spasticity-related symptoms. Overall, 96.9% of patients using THCCBD oromucosal spray had a positive global impression of change during treatment. In this pilot study, THCCBD oromucosal spray maintained or improved aspects of daily functioning. Further study in a larger trial is warranted.